Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04186884
Other study ID # 2018-0819
Secondary ID NCI-2019-0119720
Status Completed
Phase
First received
Last updated
Start date March 26, 2019
Est. completion date November 5, 2021

Study information

Verified date March 2022
Source M.D. Anderson Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This trial studies caregiver burden, quality of life, and symptom distress of patients and their informal (unpaid) caregivers at different palliative care settings. Cancer caregiving may affect a caregiver's life physically, emotionally, socially, and financially. Studying caregiver burden may help investigators learn about caregivers' opinions on stress of caregiving, and about the factors related to caregiver burdens.


Description:

PRIMARY OBJECTIVE: I. To compare the severity of subjective stress burden (emotional impact) between caregivers of patients seen at the Supportive Care Center (SCC) and those seen at the Palliative Care Unit (PCU) as measured by the Montgomery - Borgatta Caregiver Burden Scale. SECONDARY OBJECTIVES: I. To compare objective burden (impact on tangible aspects of life) between caregivers of patients seen at SCC and the PCU. II. To compare subjective demand burden (impact on the patient-caregiver relationship) between caregivers of patients seen at the SCC and the PCU. III. To compare caregiver quality of life (measured by the Short-form 36) and symptom distress (measured by the caregiver ESAS [Edmonton Symptom Assessment System]) between caregivers of patients seen at the SCC and the PCU. IV. To examine if there is a correlation between caregiver burden (Montgomery-Borgatta scale), quality of life (Short-form 36 scale) and symptom distress (ESAS caregiver scale). V. To determine which caregiver and/or patients' factors are associated with caregiver burden, quality of life, and symptom distress. OUTLINE: Patients and caregivers visiting SCC for a consult or admitted to PCU complete questionnaires over 35 minutes.


Recruitment information / eligibility

Status Completed
Enrollment 351
Est. completion date November 5, 2021
Est. primary completion date November 5, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria 1. ( SCC Patient) Patients visiting the SCC for a first consultation. 2. (SCC Patient) Patients who can identify a primary informal caregiver. 3. (SCC Patient) Diagnosis of advanced cancer defined as locally advanced, recurrent, or metastatic. 4. (SCC Patient) Be able to read and speak English. 5. (SCC Patient) 18 years of age or older. 6. (Caregiver of SCC Patient) Be identified or self-identified as a primary informal caregiver of the patient. The caregiver could be present or verbally agree to participate. 7. (Caregiver of SCC Patient) Be able to read and speak English. 8. (Caregiver of SCC Patient) 18 years of age or older. 9. (Caregiver of SCC Patient) Caregivers who are not able to complete the assessment on the day of patients' first consultation must be willing to engage in a telephone assessment with research staff +/- 3 days after. 10. (PCU Patient) Patients who have been admitted to the PCU at MD Anderson Cancer Center. 11. (PCU Patient) Patients should have a primary informal caregiver during their PCU stay. 12. (PCU Patient) Diagnosis of advanced cancer defined as locally advanced, recurrent, or metastatic. 13. (PCU Patient) Be able to read and speak English. 14. (PCU Patient) 18 years of age or older. 15. (Caregiver of PCU Patient) Be identified by the patient or self-identified as the primary informal caregiver of the patient. The caregiver should be present with the patient during PCU stay. 16. (Caregiver of PCU Patient) Be able to read and speak English. 17. (Caregiver of PCU Patient) 18 years of age or older. Exclusion Criteria 1. (SCC Patient) Refusal to participate in this study. This study requires both patient and caregiver enrollment. 2. (SCC Patient) Patients with only paid caregivers. 3. (SCC Patient) Patients with cognitive impairment as identified by research staff, treating physician or nurse. 4. (Caregiver of SCC Patient) Refusal to participate in this study. This study requires both patient and caregiver enrollment. 5. (Caregiver of SCC Patient) Patients with no caregivers or patients with only paid caregivers. 6. (PCU Patient) Refusal to participate in this study. This study requires both patient and caregiver enrollment. 7. (PCU Patient) Patients with no caregivers or patients with only paid caregivers. 8. (PCU Patient) Patients with cognitive impairment as identified by research staff, treating physician or nurse. 9. (Caregiver of PCU Patient) Refusal to participate in this study. This study requires both patient and caregiver enrollment. 10. (Caregiver of PCU Patient) Patients with no caregivers or patients with only paid caregivers.

Study Design


Intervention

Other:
Quality-of-Life Assessment
Ancillary studies
Questionnaire Administration
Complete questionnaires

Locations

Country Name City State
United States M D Anderson Cancer Center Houston Texas

Sponsors (2)

Lead Sponsor Collaborator
M.D. Anderson Cancer Center National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Severity of subjective stress burden (emotional impact) in caregivers of patients seen at the Supportive Care Center (SCC) and at the Palliative Care Unit (PCU) Measured by the Montgomery-Borgatta Caregiver Burden Scale. (4-item sub-scale questionnaire to measure the degree caregivers perceive their tasks and evaluates emotional effects of caregiving has a (Cronbach Alpha ranging from 0.68 to 0.82.) Day 1, day of enrollment
Secondary Objective burden (impact on tangible aspects of life Questionnaire Measured by Montgomery-Borgatta Caregiver Burden Scale using the 6-item objective burden sub-scale questionnaire. The sub-scale measure objective effects of caregiving in the caregivers life (i.e.:amount of time for personal privacy, recreational activities, time available to work, etc.) has a. Cronbach Alpha ranging from 0.87 to 0.90 Day 1, day of enrollment
Secondary Subjective demand burden (impact on the patient-caregiver relationship) of caregivers Measured by Montgomery-Borgatta Caregiver Burden Scale using the 4-item subjective demand burden sub-scale questionnaire. (ranges from 0.81 to 0.88) Day 1, day of enrollment
Secondary Caregiver quality of life and symptoms of distress Will compare caregiver quality of life (measured by the Short-form 36) and caregiver symptom distress (measured by the caregiver Edmonton Symptom Assessment System [ESAS]) between caregivers of patients seen at the SCC and the PCU between caregivers of patients seen at the SCC and the PCU.(Cronbach Alpha ranges from 0.70 to 0.94) Day 1, day of enrollment
Secondary Caregiver symptom distress Will examine the correlation between caregiver burden (Montgomery-Borgatta scale), quality of life (Short-form 36 scale) and symptom distress (ESAS caregiver scale). Explore if caregivers with higher burden will also have worse quality of life and higher symptom distress Day 1, day of enrollment
Secondary Factors that are associated with caregiver burden, quality of life, and symptom distress Questionnaires Explore the effect of patients'caregivers' demographics, comorbidities (Charlson Comorbidity Index), duration of care since diagnosis, strength of religious faith and engagement (Santa Clara Strength of Religious Faith Questionnaire), trust in medical profession (Trust in the Medical Profession Questionnaire with caregiver burden, quality of life, patients' demographics and/or symptom distress, clinical characteristics (comorbidities, performance status, symptom distress scores, delirium severity prognosis) on each of caregivers' burden, quality of life, and symptom distress. Responses are summed and scores range from 5-25, with higher scores indicating higher trust Day 1, day of enrollment
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03671226 - Preference of Room Setting and Waiting Time in Patients With Advanced, Locally Advanced, or Metastatic Cancer and Their Caregivers Who Are Seen in the Outpatient Supportive/Palliative Care Center N/A
Recruiting NCT05048160 - A Clinical Study of 6MW3211 Injection in the Treatment of Advanced Malignant Neoplasm Phase 1/Phase 2
Active, not recruiting NCT03287492 - RCT of QPS vs General Information Sheet N/A
Recruiting NCT01549067 - The Real Clinical Background of Advanced Colorectal Cancer Treatment Situation Survey N/A
Recruiting NCT04119037 - Cordotomy in Reducing Pain in Patients With Advanced Cancer N/A
Recruiting NCT04067336 - First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Phase 1/Phase 2
Recruiting NCT04585750 - The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) Phase 1/Phase 2
Completed NCT02823652 - Pre-Test Genetic Education and Remote Genetic Counseling in Communicating Tumor Profiling Results to Patients With Advanced Cancer N/A
Completed NCT00244972 - Tipifarnib and Sorafenib Tosylate in Treating Patients With Biopsiable Advanced Cancer Phase 1
Recruiting NCT06297642 - TQB2928 Injection Combined With Penpulimab in Treatment of Advanced Malignant Tumors. Phase 1
Active, not recruiting NCT01582191 - Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer Phase 1
Active, not recruiting NCT03856060 - Videos and Questionnaires in Assessing Patient Perception of Physician's Compassion, Communication Skills, and Professionalism During Clinic Visits N/A
Completed NCT02583269 - Muscadine Grape Skin Extract in Treating Patients With Malignancy That Is Metastatic or Cannot Be Removed by Surgery Phase 1
Withdrawn NCT03868423 - Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers Phase 2
Terminated NCT02940223 - Ethyl Icosapentate and Physical Activity in Treating Fatigue in Patients With Advanced Cancer Phase 2
Active, not recruiting NCT01552434 - Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease Phase 1
Active, not recruiting NCT03021486 - Haloperidol With or Without Chlorpromazine in Treating Delirium in Patients With Advanced, Metastatic, or Recurrent Cancer Phase 2/Phase 3
Recruiting NCT03203525 - Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer Phase 1
Completed NCT01624766 - Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers Phase 1
Not yet recruiting NCT06394713 - A Study to Evaluate the Efficacy and Safety of QLF31907 Combination Therapy in Patients With Advanced Malignant Tumors Phase 1/Phase 2